Global Human Papillomavirus (HPV) Therapeutics Market 2023-2027
Description
Global Human Papillomavirus (HPV) Therapeutics Market 2023-2027
Technavio has been monitoring the human papillomavirus (HPV) therapeutics market and is forecast to grow by $953.3 mn during 2022-2027, accelerating at a CAGR of 5.15% during the forecast period. Our report on the human papillomavirus (HPV) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advent of vaccines, development of oral vaccines for HPV, and strong disease progression.
Technavio's human papillomavirus (HPV) therapeutics market is segmented as below:
By Route of Administration
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the human papillomavirus (HPV) therapeutics market covers the following areas:
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Technavio has been monitoring the human papillomavirus (HPV) therapeutics market and is forecast to grow by $953.3 mn during 2022-2027, accelerating at a CAGR of 5.15% during the forecast period. Our report on the human papillomavirus (HPV) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advent of vaccines, development of oral vaccines for HPV, and strong disease progression.
Technavio's human papillomavirus (HPV) therapeutics market is segmented as below:
By Route of Administration
- Parenteral
- Topical
- Cervical cancer
- Anal cancer
- Vulvar and vaginal cancer
- Others
- North America
- Europe
- Asia
- Rest of World (ROW)
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the human papillomavirus (HPV) therapeutics market covers the following areas:
- Human papillomavirus (HPV) therapeutics market sizing
- Human papillomavirus (HPV) therapeutics market forecast
- Human papillomavirus (HPV) therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
161 Pages
- Market overview
- Market ecosystem
- Market definition
- Market segment analysis
- Market size 2022
- Market outlook: Forecast for 2022-2027
- Global Human Papillomavirus (HPV) therapeutics market 2017 - 2021
- Route of administration segment analysis 2017 - 2021
- Indication segment analysis 2017 - 2021
- Geography segment analysis 2017 - 2021
- Country segment analysis 2017 - 2021
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segments
- Comparison by Route of Administration
- Parenteral - Market size and forecast 2022-2027
- Topical - Market size and forecast 2022-2027
- Market opportunity by Route of Administration
- Market segments
- Comparison by Indication
- Cervical cancer - Market size and forecast 2022-2027
- Anal cancer - Market size and forecast 2022-2027
- Vulvar and vaginal cancer - Market size and forecast 2022-2027
- Others - Market size and forecast 2022-2027
- Market opportunity by Indication
- Customer landscape overview
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2022-2027
- Europe - Market size and forecast 2022-2027
- Asia - Market size and forecast 2022-2027
- Rest of World (ROW) - Market size and forecast 2022- 2027
- US - Market size and forecast 2022-2027
- Germany - Market size and forecast 2022-2027
- Canada - Market size and forecast 2022-2027
- China - Market size and forecast 2022-2027
- Brazil - Market size and forecast 2022-2027
- Market opportunity by geography
- Market drivers
- Market challenges
- Impact of drivers and challenges
- Market trends
- Overview
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- 2A Pharma ApS
- AbbVie Inc.
- Bausch Health Co. Inc.
- Bavarian Nordic AS
- BioVaxys Technology Corp.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Inovio Pharmaceuticals Inc.
- ISA Pharmaceuticals BV
- Merck and Co. Inc.
- Serum Institute of India Pvt. Ltd.
- Walvax Biotechnology Co. Ltd.
- Xiamen Innovax Biotech Co. Ltd.
- Scope of the report
- Inclusions and exclusions checklist
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
